Edwards Lifesciences (EW) VP exercises options, sells 1,019 shares under 10b5-1 plan

Rhea-AI Filing Summary

Edwards Lifesciences Corp corporate vice president Daniel J. Lippis exercised employee stock options for 1,019 shares of common stock at an exercise price of $59.2567 per share, then sold 1,019 shares of common stock at a weighted average price of $85.3822.

These transactions were executed on March 11, 2026 pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on July 30, 2025. Following the sale, Lippis directly holds 33,933.9103 shares of Edwards Lifesciences common stock, indicating he retained the vast majority of his equity position.

Insider Trade Summary 10b5-1

Net Seller: 1,019 shares ($87,004)

Net Sell 3 txns

Insider Lippis Daniel J.

Role CVP, TAVR

Sold 1,019 shs ($87K)

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Acquire)	1,019	$0.00	--
Exercise	Common Stock	1,019	$59.2567	$60K
Sale	Common Stock	1,019	$85.3822	$87K

Holdings After Transaction: Employee Stock Option (Right to Acquire) — 3,057 shares (Direct); Common Stock — 34,952.91 shares (Direct)

Footnotes (1)

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. This transaction was executed in multiple trades at prices ranging from $85.16 to $85.76. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide,uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lippis Daniel J.

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CA 92614

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP, TAVR

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/11/2026		M(1)		1,019	A	$59.2567	34,952.9103	D
Common Stock	03/11/2026		S(1)		1,019	D	$85.3822(2)	33,933.9103	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Acquire)	$59.2567	03/11/2026		M			1,019	05/08/2020	05/07/2026	Common Stock	1,019	$0.0000	3,057	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025.

2. This transaction was executed in multiple trades at prices ranging from $85.16 to $85.76. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide,uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did EW executive Daniel Lippis report on this Form 4?

Daniel J. Lippis reported exercising options for 1,019 shares of Edwards Lifesciences common stock and selling 1,019 shares on the same date. The sale occurred at a weighted average price of $85.3822 per share after exercising at $59.2567.

Was the Edwards Lifesciences (EW) insider sale by Daniel Lippis pre-planned?

Yes. The Form 4 states the transactions were carried out under a Rule 10b5-1 trading plan adopted by Daniel J. Lippis on July 30, 2025. Such plans schedule trades in advance, making the timing more routine and less discretionary.

How many Edwards Lifesciences (EW) shares does Daniel Lippis hold after this Form 4 transaction?

After exercising options and selling 1,019 shares, Daniel J. Lippis directly holds 33,933.9103 shares of Edwards Lifesciences common stock. This indicates the reported sale involved only a small portion of his overall direct equity holdings in the company.

What prices were involved in Daniel Lippis’s EW option exercise and share sale?

The options were exercised at an exercise price of $59.2567 per share, converting into 1,019 shares of common stock. Those 1,019 shares were then sold at a weighted average price of $85.3822, based on multiple trades between $85.16 and $85.76.

What does the Form 4 reveal about remaining option positions for EW executive Daniel Lippis?

The Form 4 shows a derivative transaction exercising 1,019 options and reports no remaining derivative positions in the derivative summary. This indicates the option grant referenced in the filing was fully exercised, with ongoing exposure now primarily through common stock holdings.